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As Falk states, cardiac infiltration is common in patients with primary
amyloidosis and those with the familial or senile forms, but the
prognosis is quite different between the groups (1). However, echo-
cardiograms are morphologically indistinguishable, with similar left
and right ventricular wall thickness, left ventricular volume and
ejection fraction. Thus, in our study patients, the echocardiographic
images from patients with senile or familial amyloidosis were indistin-
guishable from those with primary amyloidosis. The diagnosis of
cardiac amyloidosis was based on the presence of typical echocardio-
graphic features and was further established by the presence of
amyloid at biopsy. Because the patients were selected on the basis of
the presence of typical echocardiographic features of cardiac amyloid-
osis, we did not exclude patients with senile or familial amyloidosis
from the analysis. The purpose of the study was to analyze whether the
Doppler index could be used to characterize the impact of amyloid
infiltration on cardiac function and therefore predict the outcome.
However, we also observed similar results in an analysis of the 39
patients with primary amyloidosis: The group with an index greater
than the median value had a higher mortality risk than the group with
an index lower than the median value.
Systolic dysfunction is reflected in prolongation of the preejection
phase and shortening of the ejection phase of the cardiac cycle (2).
Diastolic dysfunction is reflected in alterations of the flow velocity
pattern of the left ventricle. A previous study (3) demonstrated
prolongation of the isovolumetric relaxation time in early amyloidosis
only, but the interval tended to be shortened because of increased left
atrial pressure in the advanced stage with restrictive filling. However,
we found that the isovolumetric relaxation time was prolonged, even in
the later stages of amyloid involvement (4). This may be explained by
the shortened ejection time, with earlier closure of the aortic valve, and
the negative peak rate of left ventricular pressure, which is significantly
abnormal in more advanced stages of cardiac amyloidosis (5). Thus,
our results demonstrate that the net result is prolongation of the
isovolumetric relaxation time, even in advanced cardiac amyloidosis,
and the new index combining systolic and diastolic time intervals was
the most powerful indicator of clinical outcome in patients with cardiac
amyloidosis compared with previously reported Doppler echocardio-
graphic variables. We have also demonstrated that the new Doppler
index was more powerful than the preejection period/ejection time and
isovolumetric contraction time/ejection time ratios at differentiating
mild and severe left ventricular dysfunction (6), probably due to the
frequent coexistence of systolic and diastolic dysfunction (7). In
addition, we have found that the index combining systolic and diastolic
time intervals was the most powerful predictor of clinical outcome in
patients with idiopathic dilated cardiomyopathy (unpublished data)
and right ventricular dysfunction (8). We would like to emphasize that
the new index is simple, reproducible and easily obtained by conven-
tional Doppler echocardiography and is a useful predictor of clinical
outcome in patients with both systolic and diastolic dysfunction.
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Digoxin Reduces Cardiac Sympathetic
Activity in Severe Congestive Heart Failure
The study by Newton et al. (1) is original, well done and provocative.
However, I find it difficult to accept the conclusion that the study
supports the idea that neurohormonal inhibition explains any benefi-
cial effects of digitalis in heart failure. For the group as a whole,
digoxin clearly had no effect on either total body or cardiac norepi-
nephrine spillover. Making sense of the differential responses in the
two subgroups is statistically problematic given the difference in group
sizes and the fact that increased spillover was also seen in the group
with higher wedge pressure. The clinical significance is even more
problematic because it would not be possible to distinguish these
patients without invasive measurements, even if one were to accept the
suggestion that patients with high wedge pressure might benefit. If we
have learned anything about mechanisms in heart failure in the past
decade, it would be that agents that either increase the activity or
potentiate the effects of the sympathetic nervous system are to be
avoided. At best, on the basis of the data from our own group (2) and
Newton et al., digoxin is neutral with regard to the sympathetic nervous
system, with the disturbing suggestion from Newton et al. that it may
also exert adverse effects in some patients. Perhaps the complexity of
the neurohormonal effects of digoxin in part explains why the DIG trial
failed to find any beneficial effect on mortality. Digoxin clearly has
vagotonic effects in heart failure (2,3), but I believe that it is time to
stop speculating about the sympathoinhibitory effects of this agent
because in the end, the only real evidence to support this mechanism
in human heart failure comes from observations by Ferguson et al. (4)
using very large, significantly pressor doses of deslanoside without
appropriate controls.
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We thank Goldsmith for his interest in our study; however, we disagree
with his interpretation of our results (1). The results reported in our
study were not derived from a subgroup analysis. Patients were
prospectively classified by the presence or absence of elevated central
pressures based on the relation between elevated filling pressures and
cardiac sympathetic activation (2). This was done to select a group with
underlying sympathetic activation because we hypothesized that
digoxin would be sympathoinhibitory in such patients. Furthermore,
because the heart failure groups were not combined, the statement
that digoxin had no effect on cardiac or total body norepinephrine
spillover in the heart failure group “as a whole” is not relevant. The
statistical analysis of the response to digoxin in the various groups is
also in no way problematic. Differences in group size and baseline
cardiac norepinephrine spillover were accounted for by the use of
general linear modeling procedures (MANOVA).
Goldsmith also suggests that our study is consistent with his
previous investigation (3) and that digoxin is neutral in terms of its
effects on sympathetic outflow because there was no change in total
body norepinephrine spillover. Our interpretation is that the total body
spillover index is insensitive to changes in specific vascular beds. The
potential for cardiac-specific responses to pharmacologic interven-
tions, without accompanying changes in total body spillover, has
recently been observed in another report from our laboratory (4).
Please recall that our study examined cardiac sympathetic responses to
digoxin. In both heart failure groups, the glycoside had clear effects on
cardiac norepinephrine spillover. It seems unreasonable, therefore, to
conclude that the effect of digoxin on cardiac sympathetic activity is
neutral.
Our investigation was a short-term study in well defined patients
with heart failure. The results of this investigation cannot be extrapo-
lated to the clinical use of long-term digoxin therapy in patients with
heart failure. These results provide insight into the complex mecha-
nism of action of digoxin and define a subset of severely ill patients in
whom a cardiac sympathoinhibitory effect may account for beneficial
responses to this agent. Interestingly, this short-term observation is
consistent with previous work demonstrating clinical responses to
digoxin in patients with a third heart sound (5) and a preliminary
report from the DIG study (6) showing greater benefit in subgroups of
patients with more severe heart failure.
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Reimbursement for Cardiac
Rehabilitation Services
Subsequent to the publication of its initial Position Report on Cardiac
Rehabilitation in 1986 (1), the American College of Cardiology (ACC)
convened two ad hoc task forces to address supplemental areas for
cardiac rehabilitation. The 1990 task force reported on cardiac reha-
bilitation services after percutaneous transluminal coronary angio-
plasty (PTCA) and valvular surgery (2), and and the 1991 task force on
cardiac rehabilitation services after cardiac transplantation (3). These
ACC position papers outlined the potential benefits of cardiac reha-
bilitation for patients with these clinical problems that constituted the
basis for the College’s advocacy of cardiac rehabilitation services for
patients with these categories of cardiac illness.
Recently, the U.S. Health Care Financing Agency (HCFA) ap-
proved reimbursement for cardiac rehabilitation services for patients
after PTCA, after valve repair or valve replacement surgery and after
heart transplantation. The state chapters of the ACC, as well as
individual members and fellows of the College, should now urge
insurers other than Medicare carriers to extend approval for reim-
bursement for cardiac rehabilitation to these categories of patients.
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